Sacubitril-Valsartan in Patients with Ischemic Cardiomyopathy Undergoing Off-Pump Coronary Artery Bypass Grafting—Is It Safe?

Abstract

Sacubitril-valsartan has been used selectively in patients undergoing coronary artery bypass grafting (CABG) and ischemic cardiomyopathy due to safety concerns. The aim of this prospective observational study was to assess the safety profile of sacubitril-valsartan in patients with reduced ejection fraction (EF <40%) undergoing CABG. Primary outcome was tolerability and safety profile. Thirty consecutive patients undergoing CABG with EF <40% were included. No mortality or readmissions occurred during 6 months follow-up. One (3.3%) patient experienced hypotension requiring discontinuation. Mild (8.9%) elevation in blood urea nitrogen, p = 0.35; along with a significant increase in serum creatinine (0.12mg/DL), p = 0.02; and potassium (0.23 mmol/L), p 0.003 was seen during follow-up. Sacubitril-valsartan is well tolerated in patients with reduced EF undergoing CABG.

Keywords

coronary artery bypass grafting - CABG - cardiomyopathy

• References

• 1 McMurray JJV, Packer M, Desai AS. et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371 (11) 993-1004
• 2 Wachter R, Senni M, Belohlavek J. et al; TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019; 21 (08) 998-1007
• 3 Almufleh A, Mielniczuk LM, Zinoviev R. et al. Profound vasoplegia during sacubitril/valsartan treatment after heart transplantation. Can J Cardiol 2018; 34 (03) 343.e5-343.e7
• 4 Kang DH, Park SJ, Shin SH. et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 2019; 139 (11) 1354-1365
• 5 Ohkuma T, Jun M, Rodgers A. et al; ADVANCE Collaborative Group. Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus. Hypertension 2019; 73 (01) 84-91
• 6 Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 2000; 160 (05) 685-693
• 7 Bodey F, Hopper I, Krum H. Neprilysin inhibitors preserve renal function in heart failure. Int J Cardiol 2015; 179: 329-330
• 8 Seferovic JP, Claggett B, Seidelmann SB. et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2017; 5 (05) 333-340
• 9 Kristensen SL, Preiss D, Jhund PS. et al; PARADIGM-HF Investigators and Committees. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 2016; 9 (01) e002560
• 10 Desai AS, Vardeny O, Claggett B. et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol 2017; 2 (01) 79-85